Project ATLAS / ASTRA — SKIN1004 scientific closeout, 15 September 2026. Perform a bounded, gap-only scientific review for assignment skin1004-keenable-wave-03: 25 exact current materials and 259 unresolved axes.
The bounded search returned 19 evidence rows — 14 exact-match authority or study rows for nine materials and 5 botanical candidate rows — drawn from five independent hosts. Across the 259 requested material/axis combinations they support 15 conditional conclusions and 1 conflicting cancer assessment; 243 axes remain evidence-insufficient. Product concentrations, exposure, impurity specifications, and preparation details were not supplied, so every authority conclusion tied to "present practices" stays conditional. No blanket product-safety claim is warranted.
Final report (Nov 18, 2024): safe in cosmetics in the present practices of use and concentration described in the assessment. SKIN1004 concentration unknown.
CIR conclusions of safety in (then) present practices, and a 2019 re-review conditioned on non-irritating, non-sensitizing formulation (QRA), sit against an old subcutaneous injection-site sarcoma study with poor topical applicability.
CIR final (Dec 19, 2011): safe in the present practices of use and concentration when formulated to be non-irritating.
One 2014 CIR final report covers all three: safe in the present practices of use and concentration in cosmetics. Concentrations in SKIN1004 products not supplied.
Expert Panel (2023, PubMed-indexed): safe in the present practices of use and concentration when formulated to be non-sensitizing. Formulation data not supplied.
Draft final amended report for panel review: safe in the present practices of use and concentration described in the assessment. Status short of final.
CIR final (Apr 2021) covers the amide at concentrations up to 0.005% and declares data insufficient above that; not evidence for Acetyl Hexapeptide-8.
Iris florentina: commercial INCI page flagging limited research and fragrant components. Pueraria lobata: oral mixture trial in postmenopausal women — wrong route and form for topical axes.
Hydroxystearic Acid carries the single conflicting-evidence cancer axis: cosmetic authority conclusions versus an old subcutaneous 12-hydroxystearic-acid injection-site sarcoma study with poor topical applicability — cir-safety.org
The Acetyl Hexapeptide-8 Amide final report is bounded to 0.005% and declares data insufficient above that concentration; it is a mismatch lead for Acetyl Hexapeptide-8, not evidence — cir-safety.org
Centella Asiatica Leaf Water has a 2023 PubMed-indexed panel conclusion, conditioned on non-sensitizing formulation — the only botanical of the five candidates with usable authority evidence — pubmed.ncbi.nlm.nih.gov
Both acute-toxicity study rows (Palmitoyl Pentapeptide-4 oral; Palmitoyl Tripeptide-1 gavage, LD50 > 2,000 mg/kg) are rat oral-route data that cannot resolve topical cosmetic axes — cir-safety.org
| Material (as stated) | Result / conclusion | Version | Route | Use in closeout | Source |
|---|
Method: bounded, gap-only review for assignment skin1004-keenable-wave-03 (closeout dated 15 September 2026); 19 evidence rows (14 exact-material authority/study rows, 5 botanical candidate rows) across five hosts. Matrix cells classify each located row against 7 endpoint classes for 13 materials; the other 12 assigned materials and all unmarked cells are evidence-insufficient, totalling 243 of 259 axes. HTTPS rows only were treated as usable; one non-HTTPS copolymer document and two commercial/mixture rows are shown as leads. Doses, durations, and populations were cut from the table for space and appear in matrix tooltips.